All In Biotech

Drug Trial Radar · NCT06214741

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

A Phase III, Randomized, Double-blind, Parallel-group, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Chinese Participants With a BMI >=28 kg/m2 or BMI >=24 kg/m2 With at Least One Weight-related Complication

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 307 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

307

Actual

Start

Feb 6, 2024

Primary completion

Jul 29, 2025

Study completion Jan 28, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jan 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study in China is open to adults who are at least 18 years old who are living with overweight or obesity. People with a body mass index (BMI) of 28 kg/m\^2 or higher or 24 kg/m\^2 or higher with at least 1 weight related problem can join the study. The main purpose of this study is to find out whether a medicine called survodutide helps people with overweight or obesity. 2 different doses of survodutide are tested in this study. Participants are put into 3 groups by chance. Each participant has an equal chance of being in each group. 2 groups get different doses of survodutide. 1 group gets placebo. Participants get survodutide or placebo as injections under the skin once a week for about 19 months. Placebo injections look like survodutide injections but do not contain any medicine. Participants are in the study for about 21 months. During this time, there are 20 visits. 14 visits are in person at the study site. Where possible, 6 visits can be done by video call, or by phone in rare cases. During this time, doctors regularly measure participant's body weight. Results are compared between the survodutide groups and placebo group to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Obesity
  • Overweight

Interventions

  • survodutideDrug

    once weekly subcutaneous injection

  • Placebo matching BI 456906Drug

    Once weekly subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weight from baseline to Week 52Time frame: At baseline and at Week 52.
  2. Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 52Time frame: At baseline and at Week 52.

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chao-Yang Hospital

    Beijing, China

  • Peking University People's Hospital

    Beijing, China

  • Beijing Pinggu Hospital

    Beijing, China

  • The First Hospital of Jilin University

    Changchun, China

  • The Second Hospital of Jilin University

    Changchun, China

  • Changzhou Second People's Hospital

    Changzhou, China

  • People's Hospital of Sichuan Province

    Chengdu, China

  • Second Affiliated Hospital Chongqing Medical University

    Chongqing, China

  • NanFang Hosptial

    Guangzhou, China

  • Forth Clinical Hospital of Harbin Medical University

    Harbin, China

  • Huzhou Central Hospital

    Huzhou, China

  • Center Hospital of Jinan

    Jinan, China

  • Jincheng General Hospital

    Jincheng, China

  • Lishui Municipal Central Hospital

    Lishui, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, China

  • Affiliated Hospital of Nantong University

    Nantong, China

  • The First Affiliated Hospital of Ningbo University

    Ningbo, China

  • Panjin Liao Oil Gem Flower Hospital

    Panjin, China

  • Shanghai Fifth People's Hospital affiliated to Fudan University

    Shanghai, China

  • Siping Central People's Hospital

    Siping, China

  • Tianjin Medical University Chu Hisen-I Memorial Hospital

    Tianjin, China

  • Tianjin Medical University General Hospital

    Tianjin, China

  • Wuhan Union Hospital

    Wuhan, China

  • The First Affiliated Hospital of Xi'an Medical University

    Xi'an, China

  • The People's Hospital Of Xuancheng City

    Xuancheng, China

  • Yichang Central People's Hospital

    Yichang, China

  • Yueyang People's Hospital

    Yueyang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.